BA
CBIO

BlackRock Advisors’s Crescent Biopharma CBIO Stock Holding History

BlackRock Advisors’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$26K Buy
43
+3
+8% +$1.87K ﹤0.01% 3401
2016
Q3 		$29K Buy
40
+13
+48% +$9.95K ﹤0.01% 3374
2016
Q2 		$20K Buy
+27
New +$18.6K ﹤0.01% 3445
2014
Q2 		– Sell
-14
Closed -$22K – 3689
2014
Q1 		$22K Buy
+14
New +$16.9K ﹤0.01% 3397

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

BlackRock Advisors's CBIO Position: Q4 2016 in Review

BlackRock Advisors increased its Crescent Biopharma (CBIO) stake by 7.5% in Q4 2016, buying an estimated $1.87K and bringing the position to 43 shares worth $26K. The position accounts for ﹤0.01% of the portfolio, ranked #3401.

BlackRock Advisors first reported a position in CBIO in Q1 2014 and has held it in 4 quarters since. The position peaked at $29K in Q3 2016. 50 funds tracked by Wall St. Rank hold CBIO as of Q4 2016.

  • BlackRock Advisors held 43 shares of Crescent Biopharma worth $26K as of Q4 2016.
  • BlackRock Advisors bought 3 Crescent Biopharma shares in Q4 2016, an estimated $1.87K.
  • Crescent Biopharma made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3401 holding.
  • BlackRock Advisors first reported a position in Crescent Biopharma in Q1 2014 and has held it in 4 quarters since.
  • BlackRock Advisors's Crescent Biopharma position peaked at $29K in Q3 2016.
  • 50 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.